SEP 11·SEC EDGARLow
Meckler Jeffrey A sold $1.3M of TVTX
Meckler Jeffrey A sold 20,000 shares of Travere Therapeutics, Inc. (TVTX) at an average of $67.31 ($65.39–$68.09, $1.35M total) across 4 trades on 2026-09-10 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$TVTX
Travere Therapeutics, Inc.
AlphAI earnings readsecond quarter 2026 · AUG 4Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarterVerdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $TVTXvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.7M 7 txs
Meckler Jeffrey A4× · $1.3M
10b5-1 share of filings86%
Top stories · $TVTXMore →
SEP 11·rttnews.com
Show Me The Money: Filspari Powers Travere Therapeutics' Growth
Travere Therapeutics (TVTX) shares hit a 52-week high of $68.59, driven by strong sales of its drug Filspari. Filspari's Q2 2026 sales were $141.1 million, up 96% year over year. The company also reported progress in its pipeline and collaborations, including a licensing agreement for Civorebrutinib. Travere's stock has risen significantly since September 2025, with a 166.7% increase as of September 10, 2026.
AUG 28·stocktwits.com
Dow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today
U.S. stock futures rose late Monday as President Trump signaled Iran may resume talks. The S&P 500 erased earlier losses, closing at 6,886.24. BlackRock upgraded U.S. equities to 'Overweight.' SanDisk (SNDK) hit a record high after positive analyst ratings. Bitmine (BMNR) gained on increased Ethereum holdings. Oracle (ORCL) and Bloom Energy (BE) rose on AI and cloud infrastructure news. Travere (TVTX) slipped despite FDA approval. Credo (CRDO) jumped on acquisition plans.
TVTX sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TVTX (Travere Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TVTX coverage spans earnings, insider activity and market movers.
In the last 30 days, TVTX insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($1.7M). The most active reporter was Meckler Jeffrey A with 4 filings. 86% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving TVTX
The insider sale may signal reduced confidence from a director, potentially pressuring the stock short term.
Price surge driven by cumulative sales momentum; no new catalyst disclosed.
First approved therapy for a rare kidney disease, a material regulatory win.
Potential negative signal as a director reduces stake, may pressure short-term price.
TVTX’s move is presented as earnings-related, which can support momentum trades but lacks detail here.
AlphAI scores every news story that mentions TVTX with an AI model for sentiment and relevance, and aggregates insider trades from Travere Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TVTX
Score
Meckler Jeffrey A sold $1.3M of TVTX
Meckler Jeffrey A sold 20,000 shares of Travere Therapeutics, Inc. (TVTX) at an average of $67.31 ($65.39–$68.09, $1.35M total) across 4 trades on 2026-09-10 under a Rule 10b5-1 trading plan.
1 min readShow Me The Money: Filspari Powers Travere Therapeutics' Growth
Travere Therapeutics (TVTX) shares hit a 52-week high of $68.59, driven by strong sales of its drug Filspari. Filspari's Q2 2026 sales were $141.1 million, up 96% year over year. The company also reported progress in its pipeline and collaborations, including a licensing agreement for Civorebrutinib. Travere's stock has risen significantly since September 2025, with a 166.7% increase as of September 10, 2026.
2 min readDow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today
U.S. stock futures rose late Monday as President Trump signaled Iran may resume talks. The S&P 500 erased earlier losses, closing at 6,886.24. BlackRock upgraded U.S. equities to 'Overweight.' SanDisk (SNDK) hit a record high after positive analyst ratings. Bitmine (BMNR) gained on increased Ethereum holdings. Oracle (ORCL) and Bloom Energy (BE) rose on AI and cloud infrastructure news. Travere (TVTX) slipped despite FDA approval. Credo (CRDO) jumped on acquisition plans.
2 min readLYONS GARY A sold $633K of TVTX
LYONS GARY A sold 10,000 shares of Travere Therapeutics, Inc. (TVTX) at an average of $63.28 ($62.53–$64.16, $0.63M total) across 5 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.
1 min readBiotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS
A dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
4 min readDoes FILSPARI-Driven Revenue Growth And Wider Losses Change The Bull Case For Travere Therapeutics (TVTX)?
Simply Wall St discusses Travere Therapeutics (TVTX) Q2 2026 results. Revenue rose to $169.58M from $114.45M, while net loss widened to $34.8M and basic loss per share to $0.37. The company cited record demand for FILSPARI in IgA nephropathy and an early FSGS launch, plus pipeline progress via civorebrutinib in-licensing and HARMONY pegtibatinase.
6 min read
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On Travere Therapeut
Travere Therapeutics (TVTX) shares rose more than 13% after hours after results for the quarter ended June 30. Total revenue was $169.58 million, above analysts’ $159.32 million estimate. U.S. net product sales rose to $161.4 million, with FILSPARI at $141.1 million. EPS was a loss of $0.10 versus a $0.23 estimate.
4 min readTravere Therapeutics, Inc. (TVTX): Results of Operations and Financial Condition
Travere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2026 Financial Results Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during
6 min readTravere Therapeutics, Inc. (TVTX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Travere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. tvtx-20260706 0001438533 false 0001438533 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K ___________________________ Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of
2 min readEverest Medicines (1952.HK) said it closed an exclusive licensing and collaboration deal with Travere
Everest Medicines (1952.HK) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East and Southeast Asia. Everest will receive $112.5M upfront and up to about $1.03B in milestone payments, plus tiered royalties.
2 min read